Nightingale Health: Spring is in the air
Nightingale's investment story is at a potential turning point. The company’s two large-scale customers (Terveystalo & Pathology Asia) seem to be progressing promisingly. Nightingale’s commercial strategy may be gaining clear proof of its functionality this year in the form of revenue growth and new customer gains. The risk level remains very high due to poor visibility, but with the current valuation and the stronger growth outlook, we consider the risk/reward ratio to be sufficiently attractive.
Login required
This content is only available for logged in users
Nightingale Health
Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.
Read more on company pageKey Estimate Figures08.03.
| 2023 | 24e | 25e | |
|---|---|---|---|
| Revenue | 4.2 | 4.7 | 8.7 |
| growth-% | 80.80 % | 12.78 % | 85.00 % |
| EBIT (adj.) | -18.5 | -17.8 | -17.6 |
| EBIT-% (adj.) | -442.95 % | -377.50 % | -201.86 % |
| EPS (adj.) | -0.30 | -0.27 | -0.27 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | - | - | - |
| EV/EBITDA | 0.77 | - | - |
